Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Buy

Debt to Equity Rating

Neutral

Price to Earnings Rating

Sell

Analyst Rating

Buy

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Exelixis Inc (EXEL)

Biological Products, (no Disgnostic Substances)

https://www.exelixis.com

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

1851 HARBOR BAY PARKWAY
ALAMEDA, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/11/2000

Market Cap

7,526,374,020

Shares Outstanding

310,970,000

Weighted SO

310,974,113

Total Employees

N/A

Upcoming Earnings

10/28/2024

Similar Tickers

TGTX --.--%

VKTX --.--%

MDGL --.--%

BTAI --.--%

BMRN --.--%

SGEN --.--%

ALNY --.--%

HALO --.--%

XFOR --.--%

Beta

0.5430

Last Div

0.0000

Range

18.64-27.53

Chg

0.0750

Avg Vol

1778059

Mkt Cap

7526374020

Exch

NASDAQ

Country

US

Phone

650 837 7000

DCF Diff

-50.4228

DCF

76.8028

Div Yield

0.0000

P/S

3.7371

EV Multiple

16.5970

P/FV

3.6000

Div Yield %

0.0000

P/E

21.8033

PEG

2.4325

Payout

0.0000

Current Ratio

4.2737

Quick Ratio

4.2141

Cash Ratio

0.4556

DSO

73.8860

DIO

94.7025

Op Cycle

168.5885

DPO

131.7400

CCC

36.8485

Gross Margin

0.9606

Op Margin

0.1837

Pretax Margin

0.2239

Net Margin

0.1738

Eff Tax Rate

0.2239

ROA

0.1262

ROE

0.1580

ROCE

0.1524

NI/EBT

0.7761

EBT/EBIT

1.2188

EBIT/Rev

0.1837

Debt Ratio

0.0714

D/E

0.0934

LT Debt/Cap

0.0854

Total Debt/Cap

0.0854

Int Coverage

14.0674

CF/Debt

1.5974

Equity Multi

1.3082

Rec Turnover

4.9400

Pay Turnover

2.7706

Inv Turnover

3.8542

FA Turnover

15.4671

Asset Turnover

0.7262

OCF/Share

1.0937

FCF/Share

0.6381

Cash/Share

3.4645

OCF/Sales

0.1571

FCF/OCF

0.5834

CF Coverage

1.5974

ST Coverage

0.0000

CapEx Coverage

2.4005

Div&CapEx Cov

2.4005

P/BV

3.6000

P/B

3.6000

P/S

3.7371

P/E

21.8033

P/FCF

40.7847

P/OCF

24.1251

P/CF

24.1251

PEG

2.4325

P/S

3.7371

EV Multiple

16.5970

P/FV

3.6000

DPS

0.0000

Latest Headlines (EST)

Benzinga May 18, 20:06 CoreWeave, Super Micro Computer And Coinbase Are Among Top 11 Large-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio? GlobeNewswire Inc. Mar 10, 00:30 Global Prostate Cancer Market to Reach USD 29.2 Billion by 2035, Driven by Aging Population and Awareness | Future Market Insights, Inc. The Motley Fool Feb 21, 23:31 Why Exelixis Stock Trounced the Market on Thursday Benzinga Jan 08, 14:12 Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today? MarketWatch Dec 28, 07:46 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky MarketWatch Dec 28, 06:34 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky Benzinga Dec 13, 14:00 6 Analysts Have This to Say About Exelixis Benzinga Nov 02, 15:00 Where Exelixis Stands With Analysts The Motley Fool Nov 02, 00:30 Exelixis (EXEL) Q3 2023 Earnings Call Transcript The Motley Fool Nov 02, 00:30 Exelixis (EXEL) Q3 2023 Earnings Call Transcript The Motley Fool Nov 02, 00:30 Exelixis (EXEL) Q3 2023 Earnings Call Transcript Zacks Investment Research Nov 01, 19:00 Compared to Estimates, Exelixis (EXEL) Q3 Earnings: A Look at Key Metrics Zacks Investment Research Nov 01, 19:00 Compared to Estimates, Exelixis (EXEL) Q3 Earnings: A Look at Key Metrics Zacks Investment Research Nov 01, 19:00 Compared to Estimates, Exelixis (EXEL) Q3 Earnings: A Look at Key Metrics The Motley Fool Oct 28, 05:06 4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip The Motley Fool Oct 28, 05:06 4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

Revenue Product Segmentation